Nemtabrutinib (ARQ 531) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase ( BTK ), with IC 50 s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.
Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Btk
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.